The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.本發明涉及用於免疫治療方法的肽、核酸和細胞。特別是，本發明涉及癌症的免疫療法。本發明還涉及單獨使用或與其他腫瘤相關肽(激抗腫瘤免疫反應疫苗複合物的活性藥物成分)合使用的腫瘤相關細胞毒性T輔助細胞(CTL)肽表位。本發明涉及33種新型肽序列及其變體，它們源自可用於引發抗腫瘤免疫反應的疫苗組合物中的人腫瘤HLA-I類分子。
